20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Acquired by Ieq Capital LLC

Ieq Capital LLC acquired a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,749 shares of the company's stock, valued at approximately $361,000.

A number of other hedge funds have also bought and sold shares of TVTX. Creative Planning lifted its position in shares of Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company's stock worth $335,000 after acquiring an additional 995 shares in the last quarter. Rhumbline Advisers lifted its holdings in Travere Therapeutics by 2.2% during the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company's stock worth $2,112,000 after purchasing an additional 2,640 shares in the last quarter. R Squared Ltd bought a new position in Travere Therapeutics in the 4th quarter worth about $53,000. Diversified Trust Co grew its holdings in Travere Therapeutics by 27.5% during the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company's stock valued at $256,000 after buying an additional 3,169 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Travere Therapeutics by 20.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company's stock valued at $279,000 after buying an additional 3,458 shares during the period.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher R. Cline sold 5,192 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $104,463.04. Following the sale, the chief financial officer now owns 90,038 shares in the company, valued at approximately $1,811,564.56. This trade represents a 5.45 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 206,335 shares of company stock valued at $4,453,012. Corporate insiders own 3.75% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have commented on TVTX. JPMorgan Chase & Co. raised their price target on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Piper Sandler increased their target price on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a report on Thursday, November 14th. Citigroup lifted their price target on Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, February 24th. Finally, Scotiabank increased their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $30.62.

Travere Therapeutics Trading Down 7.6 %

NASDAQ TVTX traded down $1.64 during trading on Monday, hitting $19.77. The company had a trading volume of 1,120,598 shares, compared to its average volume of 1,636,618. The company's fifty day moving average is $20.05 and its 200-day moving average is $17.12. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -4.82 and a beta of 0.72.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The company had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. On average, sell-side analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.